Monopar Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell MNPR and other ETFs, options, and stocks.About MNPR
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages.
CEOChandler Drew Robinson
CEOChandler Drew Robinson
Employees16
Employees16
HeadquartersWilmette, Illinois
HeadquartersWilmette, Illinois
Founded2014
Founded2014
Employees16
Employees16
MNPR Key Statistics
Market cap528.99M
Market cap528.99M
Price-Earnings ratio-23.11
Price-Earnings ratio-23.11
Dividend yield—
Dividend yield—
Average volume148.93K
Average volume148.93K
High today$79.90
High today$79.90
Low today$75.47
Low today$75.47
Open price$75.47
Open price$75.47
Volume153.35K
Volume153.35K
52 Week high$105.00
52 Week high$105.00
52 Week low$20.16
52 Week low$20.16
Stock Snapshot
As of today, Monopar Therapeutics(MNPR) shares are valued at $79.47. The company's market cap stands at 528.99M, with a P/E ratio of -23.11.
On 2025-12-04, Monopar Therapeutics(MNPR) stock moved within a range of $75.47 to $79.90. With shares now at $79.47, the stock is trading +5.3% above its intraday low and -0.5% below the session's peak.
Trading volume for Monopar Therapeutics(MNPR) stock has reached 153.35K, versus its average volume of 148.93K.
Over the past 52 weeks, Monopar Therapeutics(MNPR) stock has traded between a high of $105.00 and a low of $20.16.
Over the past 52 weeks, Monopar Therapeutics(MNPR) stock has traded between a high of $105.00 and a low of $20.16.
Analyst ratings
100%
of 13 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own MNPR. This list is generated using Robinhood data, and it’s not a recommendation.